Framingham genetic medicine firm Variantyx has launched a new genome-based test for chromosomal abnormalities. The IriSight CNV Analysis tests for abnormalities potentially causing pregnancy loss or genetic disorders.
The new product is an alternative to the typical genome testing – which is called chromosomal microarray – and can test for a broader range of chromosomal abnormalities, according to a Friday press release from Variantyx. Chromosomal testing for fetuses has been used for several decades to test for serious genetic disorders, including Down syndrome.
“IriSight CNV Analysis provides the first true alternative to CMA,” Variantyx Medical Director Dr. Allan Fisher said in the press release.
Chromosomal testing is an accepted diagnostic tool in fetal medicine and can be used to inform health care decisions and treatment options.
